Computer Aided Drug Discovery Market: Industry Trends and Global Forecasts - Distribution by Drug Discovery Steps, Company Size, Therapeutic Area, and Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Drug Discovery and Development Timelines
• 3.3. Overview of In Silico Drug Discovery Tools
  • 3.3.1. Historical Evolution of the In Silico Approach
  • 3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
  • 3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development
• 3.4. Applications of In Silico Tools in the Drug Discovery Process
  • 3.4.1. Target Identification
    • 3.4.1.1. Chemoinformatics-based Tools
    • 3.4.1.2. Network-based Drug Discovery
    • 3.4.1.3. Computational Platforms and Interaction Repositories
  • 3.4.2. Target Validation
  • 3.4.3. Hit Generation
    • 3.4.3.1. High-Throughput Screening
    • 3.4.3.2. Fragment Based Screening
    • 3.4.3.3. Virtual Screening
  • 3.4.4. Hit-to-Lead
    • 3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
    • 3.4.4.2. Other Novel Approaches
  • 3.4.5. Lead Optimization
    • 3.4.5.1. Pharmacophore Modeling
    • 3.4.5.2. Docking
    • 3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)
    • 3.4.5.4. Molecular Modeling
• 3.5. Advantages of using In Silico Tools for Drug Discovery Operations
• 3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations
• 3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
• 3.8. Concluding Remarks

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Company Size and Location of Headquarters
  • 4.2.5. Analysis by Type of Business Model
  • 4.2.6. Analysis by Drug Discovery Steps
  • 4.2.7. Analysis by Type of Large Molecule
    • 4.2.7.1. Analysis by Type of Antibody
    • 4.2.7.2. Analysis by Type of Protein
  • 4.2.8. Analysis by Type of In Silico Approach Used
  • 4.2.9. Analysis by Types of In Silico Services Offered
  • 4.2.10. Analysis by Type of Clientele
• 4.3. In Silico Drug Discovery Services: List of Software / Technologies

5. KEY INSIGHTS

• 5.1. Chapter Overview
• 5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
• 5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
• 5.4. World Map Representation: Regional Analysis of Outsourcing Activity
• 5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele

6. COMPANY PROFILES

• 6.1. Chapter Overview
• 6.2. Key In Silico Service Providers Based in North America
  • 6.2.1. BioDuro
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Funding and Investment Information
    • 6.2.1.3. In Silico-based Service Portfolio
    • 6.2.1.4. Recent Developments and Future Outlook
    • 6.2.1.5. Peer Group Benchmark Comparison
  • 6.2.2. Creative Biostructure
    • 6.2.2.1. Company Overview
    • 6.2.2.2. Funding and Investment Information
    • 6.2.2.3. In Silico-based Service Portfolio
    • 6.2.2.4. Recent Developments and Future Outlook
    • 6.2.2.5. Peer Group Benchmark Comparison
  • 6.2.3. GenScript
    • 6.2.3.1. Company Overview
    • 6.2.3.2. Funding and Investment Information
    • 6.2.3.3. In Silico-based Service Portfolio
    • 6.2.3.4. Recent Developments and Future Outlook
    • 6.2.3.5. Peer Group Benchmark Comparison
  • 6.2.4. LakePharma
    • 6.2.4.1. Company Overview
    • 6.2.4.2. Funding and Investment Information
    • 6.2.4.3. In Silico-based Service Portfolio
    • 6.2.4.4. Recent Developments and Future Outlook
    • 6.2.4.5. Peer Group Benchmark Comparison
• 6.3. Leading Players Based in Europe
  • 6.3.1. Abzena
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Funding and Investment Information
    • 6.3.1.3. In Silico-based Service Portfolio
    • 6.3.1.4. Recent Developments and Future Outlook
    • 6.3.1.5. Peer Group Benchmark Comparison
  • 6.3.2. BioNTech
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Funding and Investment Information
    • 6.3.2.3. Recent Developments and Future Outlook
    • 6.3.2.4. Peer Group Benchmark Comparison
  • 6.3.3. Sygnature Discovery
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Funding and Investment Information
    • 6.3.3.3. In Silico-based Service Portfolio
    • 6.3.3.4. Recent Developments and Future Outlook
    • 6.3.3.5. Peer Group Benchmark Comparison
• 6.4. Leading Players Based in Asia-Pacific
  • 6.4.1. ChemPartner
    • 6.4.1.1. Company Overview
    • 6.4.1.2. In Silico-based Service Portfolio
    • 6.4.1.3. Recent Developments and Future Outlook
    • 6.4.1.4. Peer Group Benchmark Comparison
  • 6.4.2. Sundia MediTech
    • 6.4.2.1. Company Overview
    • 6.4.2.2. Funding and Investment Information
    • 6.4.2.3. In Silico-based Service Portfolio
    • 6.4.2.4. Recent Development and Future Outlook
    • 6.4.2.5. Peer Group Benchmark Comparison
  • 6.4.3. Viva Biotech
    • 6.4.3.1. Company Overview
    • 6.4.3.2. Funding and Investment Information
    • 6.4.3.3. In Silico-based Service Portfolio
    • 6.4.3.4. Recent Development and Future Outlook
    • 6.4.3.5. Peer Group Benchmark Comparison

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Key Parameters
• 7.3. Methodology
• 7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
• 7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
• 7.6. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World

8. KEY OPPORTUNITY AREAS

• 8.1. Chapter Overview
• 8.2. Key Assumptions and Parameters
• 8.3. Methodology
• 8.4. Antibodies
  • 8.4.1. Developer Landscape
    • 8.4.1.1. Number of Pipeline Molecules
    • 8.4.1.2. Affiliated Market Size and Growth Rate
  • 8.4.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
• 8.5. Peptides
  • 8.5.1. Developer Landscape
    • 8.5.1.1. Number of Pipeline Molecules
    • 8.5.1.2. Affiliated Market Size and Growth Rate
  • 8.5.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
• 8.6. Proteins
  • 8.6.1. Developer Landscape
    • 8.6.1.1. Number of Pipeline Molecules
    • 8.6.1.2. Affiliated Market Size and Growth Rate
  • 8.6.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
• 8.7. Other Advanced Therapies
  • 8.7.1. Developer Landscape
    • 8.7.1.1. Number of Pipeline Molecules
    • 8.7.1.2. Affiliated Market Size and Growth Rate
  • 8.7.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

9. EMERGING BUSINESS MODELS AND STRATEGIES

• 9.1. Chapter Overview
• 9.2. Key Assumptions and Methodology
• 9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
  • 9.3.1. Strategies for Short Term Success
  • 9.3.2. Strategies for Long Term Success
• 9.4. Concluding Remarks

10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES

• 10.1. Chapter Overview
• 10.2. Small Molecule and Large Molecule Drugs / Therapies
  • 10.2.1. Comparison of Key Specifications
  • 10.2.2. Comparison of Manufacturing Processes
  • 10.2.3. Comparison of Drug Discovery Processes
• 10.3. Approaches to Improve Discovery Process of Large Molecules

11. SURVEY INSIGHTS

• 11.1. Chapter Overview
• 11.2. Overview of Respondents
  • 11.2.1. Designation of Respondents
• 11.3. Survey Insights
  • 11.3.1. Drug Discovery Steps
  • 11.3.2. Type of Molecules Handled
  • 11.3.3. In Silico Drug Design Focused Service Portfolio
  • 11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
  • 11.3.5. Current Market Opportunity
  • 11.3.6. Likely Growth Rate
  • 11.3.7. Cost Saving Potential of the In Silico Approach

12. COST SAVING ANALYSIS

• 12.1. Chapter Overview
• 12.2. Key Assumptions
• 12.3. Methodology
• 12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035
• 12.5. Concluding Remarks

13. MARKET FORECAST

• 13.1. Chapter Overview
• 13.2. Forecast Methodology and Key Assumptions
• 13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035
  • 13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, Till 2035
    • 13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, Till 2035
    • 13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, Till 2035
    • 13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, Till 2035
    • 13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, Till 2035
    • 13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, Till 2035
  • 13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, Till 2035
    • 13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, Till 2035
    • 13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, Till 2035
    • 13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, Till 2035
    • 13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, Till 2035
    • 13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, Till 2035
  • 13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, Till 2035
    • 13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, Till 2035
    • 13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, Till 2035
    • 13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, Till 2035
  • 13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, Till 2035
    • 13.3.4.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, Till 2035
    • 13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, Till 2035
    • 13.3.4.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, Till 2035
    • 13.3.4.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, Till 2035
    • 13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, Till 2035
    • 13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), Till 2035
    • 13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, Till 2035
    • 13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, Till 2035
    • 13.3.4.9. In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, Till 2035
    • 13.3.4.10. In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, Till 2035
    • 13.3.4.11. In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, Till 2035
    • 13.3.4.12. In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders Till 2035
    • 13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, Till 2035
    • 13.3.4.14. In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, Till 2035
    • 13.3.4.15. In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, Till 2035
    • 13.3.4.16. In Silico Drug Discovery Services Market for Large Molecules: Share of Others, Till 2035
  • 13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, Till 2035
    • 13.3.5.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, Till 2035
    • 13.3.5.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, Till 2035
  • 13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, Till 2035
    • 13.3.6.1. In Silico Drug Discovery Services Market for Large Molecules: Share of North America, Till 2035
      • 13.3.6.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of US, Till 2035
      • 13.3.6.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, Till 2035
    • 13.3.6.2. In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, Till 2035
      • 13.3.6.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, Till 2035
      • 13.3.6.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share in France, Till 2035
      • 13.3.6.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, Till 2035
      • 13.3.6.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, Till 2035
      • 13.3.6.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, Till 2035
      • 13.3.6.2.6. In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, Till 2035
    • 13.3.6.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, Till 2035
      • 13.3.6.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share in China, Till 2035
      • 13.3.6.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share in India, Till 2035
      • 13.3.6.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, Till 2035

14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY

• 14.1. Chapter Overview
• 14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
• 14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
  • 14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve Overall Efficiency and Productivity
  • 14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
  • 14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
• 14.4. Concluding Remarks

15. EXECUTIVE INSIGHTS

• 15.1. Chapter Overview
• 15.2. Company A
  • 15.2.1. Company Snapshot
  • 15.2.2. Interview Transcript: Founder and Chief Executive Officer
• 15.3. Company B
  • 15.3.1. Company Snapshot
  • 15.3.2. Interview Transcript: Chief Executive Officer and Chief Technical Officer
• 15.4. Company C
  • 15.4.1. Company Snapshot
  • 15.4.2. Interview Transcript: Senior Vice President, Drug Discovery
• 15.5. Company D
  • 15.5.1. Company Snapshot
  • 15.5.2. Interview Transcript: Founder

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

List of Tables

• Table 4.1. In Silico Drug Discovery Service Providers for Large Molecules: List of Industry Players
• Table 4.2. In Silico Drug Discovery Services for Large Molecules: Information on Drug Discovery Steps
• Table 4.3. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of In Silico Approach
• Table 4.4. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of Clientele
• Table 4.5. In Silico Drug Discovery Services for Large Molecules: Information on Type of Large Molecule
• Table 4.6. In Silico Drug Discovery Services for Large Molecules: Information on In Silico-based Service Offerings
• Table 4.7. In Silico Drug Discovery Services for Large Molecules: Additional Information
• Table 4.8. In Silico Drug Discovery Services: List of Software / Technologies
• Table 6.1. In Silico Service Providers: List of Companies Profiled
• Table 6.2. BioDuro: Key Highlights
• Table 6.3. BioDuro: List of Funding Instances and Investors
• Table 6.4. BioDuro: Recent Developments and Future Outlook
• Table 6.5. Creative Biostructure: Key Highlights
• Table 6.6. Creative Biostructure: List of Funding Instances and Investors
• Table 6.7. Creative Biostructure: Recent Developments and Future Outlook
• Table 6.8. GenScript: Key Highlights
• Table 6.9. GenScript: List of Funding Instances and Investors
• Table 6.10. GenScript: Recent Developments and Future Outlook
• Table 6.11. LakePharma: Key Highlights
• Table 6.12. LakePharma: List of Funding Instances and Investors
• Table 6.13. LakePharma: Recent Developments and Future Outlook
• Table 6.14. Abzena: Key Highlights
• Table 6.15. Abzena: List of Funding Instances and Investors
• Table 6.16. Abzena: Recent Developments and Future Outlook
• Table 6.17. BioNTech: Key Highlights
• Table 6.18. BioNTech: List of Funding Instances and Investors
• Table 6.19. BioNTech: Recent Developments and Future Outlook
• Table 6.20. Sygnature Discovery: Key Highlights
• Table 6.21. Sygnature Discovery: List of Funding Instances and Investors
• Table 6.22. Sygnature Discovery: Recent Developments and Future Outlook
• Table 6.23. ChemPartner: Key Highlights
• Table 6.24. ChemPartner: Recent Developments and Future Outlook
• Table 6.25. Sundia MediTech: Key Highlights
• Table 6.26. Sundia MediTech: List of Funding Instances and Investors
• Table 6.27. Sundia MediTech: Recent Developments and Future Outlook
• Table 6.28. Viva Biotech: Key Highlights
• Table 6.29. Viva Biotech: List of Funding Instances and Investors
• Table 6.30. Viva Biotech: Recent Developments and Future Outlook
• Table 10.1. Comparison of Strengths and Weaknesses of Small Molecules and Large Molecules
• Table 10.2. Comparison of Development Characteristics of Small Molecules and Large Molecules
• Table 10.3. Challenges in the Discovery of Different Types of Large Molecules
• Table 11.1. Survey Insights: Overview of Respondents
• Table 11.2. Survey Insights: Designation and Seniority Levels
• Table 11.3. Survey Insights: Drug Discovery Steps Covered in Service Portfolio
• Table 11.4. Survey Insights: Expertise Related to Different Types of Molecules
• Table 11.5. Survey Insights: In Silico Drug Discovery Focused Service Portfolio
• Table 11.6 Survey Insights: Other In Silico Services Offered
• Table 11.7. Survey Insights: Likely Adoption of In Silico Tools for Large Molecule Drug Discovery
• Table 11.8. Survey Insights: Opinions on Current Market Opportunity
• Table 11.8. Survey Insights: Opinions on Likely Growth Rate
• Table 11.9. Survey Insights: Opinions on Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
• Table 12.1. Likely Cost Reduction using In Silico Services for Large Molecules and Small Molecules
• Table 12.2 Drug Discovery Steps: Key Parameters
• Table 14.1. Companies Offering Artificial Intelligence and In Silico Services
• Table 14.2. Companies Offering Cloud Computing Platforms and In Silico Services
• Table 15.1. ProSciens: Company Snapshot
• Table 15.2. Conifer Point Pharmaceuticals: Company Snapshot
• Table 16.1. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Year of Establishment
• Table 16.2. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Company Size
• Table 16.3. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Location of Headquarters
• Table 16.4. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Business Model
• Table 16.5. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Drug Discovery Steps
• Table 16.6. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Large Molecule
• Table 16.7. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Antibody
• Table 16.8. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Protein
• Table 16.9. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Designing Approach Used
• Table 16.10. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by In Silico Service Offering
• Table 16.11. In Silico Drug Discovery Service Providers for Large Molecules: Distribution by Type of Clientele
• Table 16.12. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
• Table 16.13. World Map Representation: Regional Analysis of Outsourcing Activity
• Table 16.14. Grid Representation: Distribution by Type of Large Molecule and Designing Approach
• Table 16.15. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval
• Table 16.16. Survey Insights: Distribution of Respondents by Year of Establishment of Company
• Table 16.17. Survey Insights: Distribution of Respondents by Employee Size
• Table 16.18. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
• Table 16.19. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
• Table 16.20. Survey Insights: Distribution by Designation and Seniority Level of Respondents
• Table 16.21. Survey Insights: Distribution by Drug Discovery Steps
• Table 16.22. Survey Insights: Distribution by Type of Molecule
• Table 16.23. Survey Insights: Distribution by In Silico-based Service Portfolio
• Table 16.24. Survey Insights: Distribution by Likely Adoption of In Silico Tools
• Table 16.25. Survey Insights: Distribution by Current Market Opportunity
• Table 16.26. Survey Insights: Distribution by Likely Growth Rate
• Table 16.27. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
• Table 16.28. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035 (USD Billion)
• Table 16.29. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035 (USD Million)
• Table 16.30. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps
• Table 16.31. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, Till 2035 (USD Million)
• Table 16.32. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, Till 2035 (USD Million)
• Table 16.33. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, Till 2035 (USD Million)
• Table 16.34. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, Till 2035 (USD Million)
• Table 16.35. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, Till 2035 (USD Million)
• Table 16.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule
• Table 16.37. In Silico Drug Discovery Services Market for Antibodies, Till 2035 (USD Million)
• Table 16.38. In Silico Drug Discovery Services Market for Proteins, Till 2035 (USD Million)
• Table 16.39. In Silico Drug Discovery Services Market for Peptides, Till 2035 (USD Million)
• Table 16.40. In Silico Drug Discovery Services Market for Nucleic Acid, Till 2035 (USD Million)
• Table 16.41. In Silico Drug Discovery Services Market for Vectors, Till 2035 (USD Million)
• Table 16.42. In Silico Drug Discovery Services Market for Other Large Molecules, Till 2035 (USD Million)
• Table 16.43. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size
• Table 16.44. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, Till 2035 (USD Million)
• Table 16.45. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, Till 2035 (USD Million)
• Table 16.46. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, Till 2035 (USD Million)
• Table 16.47. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Areas
• Table 16.48. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, Till 2035 (USD Million)
• Table 16.49. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, Till 2035 (USD Million)
• Table 16.50. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, Till 2035 (USD Million)
• Table 16.51. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, Till 2035 (USD Million)
• Table 16.52. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, Till 2035 (USD Million)
• Table 16.53. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, Till 2035 (USD Million)
• Table 16.54. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, Till 2035 (USD Million)
• Table 16.55. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, Till 2035 (USD Million)
• Table 16.56. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, Till 2035 (USD Million)
• Table 16.57. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, Till 2035 (USD Million)
• Table 16.58. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, Till 2035 (USD Million)
• Table 16.59. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, Till 2035 (USD Million)
• Table 16.60. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, Till 2035 (USD Million)
• Table 16.61. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, Till 2035 (USD Million)
• Table 16.62. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, Till 2035 (USD Million)
• Table 16.63. In Silico Drug Discovery Services Market for Large Molecules for Others, Till 2035 (USD Million)
• Table 16.64. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor
• Table 16.65. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, Till 2035 (USD Million)
• Table 16.66. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, Till 2035 (USD Million)
• Table 16.67. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions
• Table 16.68. In Silico Drug Discovery Services Market for Large Molecules in North America, (USD Million)
• Table 16.69. In Silico Drug Discovery Services Market for Large Molecules in the US, Till 2035 (USD Million)
• Table 16.70. In Silico Drug Discovery Services Market for Large Molecules in Canada, Till 2035 (USD Million)
• Table 16.71. In Silico Drug Discovery Services Market for Large Molecules in Europe, (USD Million)
• Table 16.72. In Silico Drug Discovery Services Market for Large Molecules in Germany, Till 2035 (USD Million)
• Table 16.73. In Silico Drug Discovery Services Market for Large Molecules in France, Till 2035 (USD Million)
• Table 16.74. In Silico Drug Discovery Services Market for Large Molecules in the UK, Till 2035 (USD Million)
• Table 16.75. In Silico Drug Discovery Services Market for Large Molecules in Italy, Till 2035 (USD Million)
• Table 16.76. In Silico Drug Discovery Services Market for Large Molecules in Spain, Till 2035 (USD Million)
• Table 16.77. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, Till 2035 (USD Million)
• Table 16.78. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World (USD Million)
• Table 16.79. In Silico Drug Discovery Services Market for Large Molecules in China, Till 2035 (USD Million)
• Table 16.80. In Silico Drug Discovery Services Market for Large Molecules in India, Till 2035 (USD Million)
• Table 16.81. In Silico Drug Discovery Services Market for Large Molecules in Japan, Till 2035 (USD Million)
• Table 16.82. In Silico Drug Discovery Services Market for Large Molecules in Other Asian Countries, Till 2035 (USD Million)

List of Figures

• Figure 3.1. Drug Discovery and Development Timeline
• Figure 3.2. Historical Evolution of Computational Drug Discovery Approaches
• Figure 3.3. Steps Involved in the Virtual Drug Discovery Process
• Figure 3.4. Comparison of Traditional and In Silico Drug Discovery Approaches
• Figure 3.5. Classification of In Silico Drug Discovery Approaches
• Figure 3.6. Flowchart of the In Silico Drug Discovery Approach
• Figure 3.7. In Silico Service Map for Drug Discovery Process
• Figure 3.8. Advantages of using In Silico Drug Discovery Services
• Figure 3.9. Types of Large Molecule Drugs
• Figure 4.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
• Figure 4.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
• Figure 4.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
• Figure 4.4 In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size and Location of Headquarters
• Figure 4.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
• Figure 4.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
• Figure 4.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
• Figure 4.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
• Figure 4.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
• Figure 4.10. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of In Silico Approach Used
• Figure 4.11. In Silico Drug Discovery Services for Large Molecules: Distribution by Types of In Silico Services Offered
• Figure 5.1. Logo Landscape: Distribution by Company Size and Location of Headquarters
• Figure 5.2. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
• Figure 5.3. World Map Representation: Regional Analysis of Outsourcing Activity
• Figure 5.4. Grid Representation: Distribution by Type of Large Molecule, Designing Approach Used and Type of Clientele
• Figure 6.1. BioDuro: In Silico-based Service Portfolio
• Figure 6.2. BioDuro: Peer Group Benchmark Comparison
• Figure 6.3. Creative Biostructure: In Silico-based Service Portfolio
• Figure 6.4. Creative Biostructure: Peer Group Benchmark Comparison
• Figure 6.5. GenScript: In Silico-based Service Portfolio
• Figure 6.6. GenScript: Peer Group Benchmark Comparison
• Figure 6.7. LakePharma: In Silico-based Service Portfolio
• Figure 6.8. LakePharma: Peer Group Benchmark Comparison
• Figure 6.9. Abzena: In Silico-based Service Portfolio
• Figure 6.10. Abzena: Company Benchmarking Output
• Figure 6.11. BioNTech: Peer Group Benchmark Comparison
• Figure 6.12. Sygnature Discovery: In Silico-based Service Portfolio
• Figure 6.13. Sygnature Discovery: Peer Group Benchmark Comparison
• Figure 6.14. ChemPartner: In Silico-based Service Portfolio
• Figure 6.15. ChemPartner: Peer Group Benchmark Comparison
• Figure 6.16. Sundia MediTech: In Silico-based Service Portfolio
• Figure 6.17. Sundia MediTech: Peer Group Benchmark Comparison
• Figure 6.18. Viva Biotech: In Silico-based Service Portfolio
• Figure 6.19. Viva Biotech: Peer Group Benchmark Comparison
• Figure 7.1. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
• Figure 7.2. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
• Figure 7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
• Figure 8.1. In Silico Drug Discovery Service Providers for Antibodies: 3D Bubble Representation
• Figure 8.2. In Silico Drug Discovery Service Providers for Peptides: 3D Bubble Representation
• Figure 8.3. In Silico Drug Discovery Service Providers for Proteins: 3D Bubble Representation
• Figure 8.4. In Silico Drug Discovery Service Providers for Other Advanced Therapies: 3D Bubble Representation
• Figure 9.1. In Silico Drug Discovery Service Providers: Popular Strategies or Business Models
• Figure 10.1. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval
• Figure 10.2. Small Molecules versus Large Molecules: Comparison of Key Characteristics
• Figure 10.3. Small Molecules versus Large Molecules: Comparison of Manufacturing Process
• Figure 11.1. Survey Insights: Distribution of Respondents by Year of Establishment of Company
• Figure 11.2. Survey Insights: Distribution of Respondents by Company Size
• Figure 11.3. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
• Figure 11.4. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
• Figure 11.5. Survey Insights: Distribution by Designation and Seniority Level of Respondents
• Figure 11.6. Survey Insights: Distribution by Drug Discovery Steps
• Figure 11.7. Survey Insights: Distribution by Type of Molecules Handled
• Figure 11.8. Survey Insights: Distribution by In Silico-based Service Portfolio
• Figure 11.9. Survey Insights: Distribution by Likely Adoption of In Silico Tools
• Figure 11.10. Survey Insights: Distribution by Current Market Opportunity
• Figure 11.11. Survey Insights: Distribution by Likely Growth Rate
• Figure 11.12. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
• Figure 12.1. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery: Growth Scenarios
• Figure 12.2. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035 (USD Billion)
• Figure 13.1. Roots Analysis Forecasting Approach
• Figure 13.2. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035 (USD Million)
• Figure 13.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps (USD Million)
• Figure 13.4. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, Till 2035 (USD Million)
• Figure 13.5. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, Till 2035 (USD Million)
• Figure 13.6. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, Till 2035 (USD Million)
• Figure 13.7. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, Till 2035 (USD Million)
• Figure 13.8. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, Till 2035 (USD Million)
• Figure 13.9. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule (USD Million)
• Figure 13.10. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, Till 2035 (USD Million)
• Figure 13.11. In Silico Drug Discovery Services Market for Large Molecules for Proteins, Till 2035 (USD Million)
• Figure 13.12. In Silico Drug Discovery Services Market for Large Molecules for Peptides, Till 2035 (USD Million)
• Figure 13.13. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, Till 2035 (USD Million)
• Figure 13.14. In Silico Drug Discovery Services Market for Large Molecules for Vectors, Till 2035 (USD Million)
• Figure 13.15. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size (USD Million)
• Figure 13.16. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, Till 2035 (USD Million)
• Figure 13.17. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, Till 2035 (USD Million)
• Figure 13.18. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, Till 2035 (USD Million)
• Figure 13.19. In Silico Drug Discovery Services Market for Large Molecules: Market Attractiveness Analysis by Type of Therapeutic Area (USD Million)
• Figure 13.20. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, Till 2035 (USD Million)
• Figure 13.21. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, Till 2035 (USD Million)
• Figure 13.22. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, Till 2035 (USD Million)
• Figure 13.23. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, Till 2035 (USD Million)
• Figure 13.24. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, Till 2035 (USD Million)
• Figure 13.25. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, Till 2035 (USD Million)
• Figure 13.26. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, Till 2035 (USD Million)
• Figure 13.27. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, Till 2035 (USD Million)
• Figure 13.28. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, Till 2035 (USD Million)
• Figure 13.29. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, Till 2035 (USD Million)
• Figure 13.30. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, Till 2035 (USD Million)
• Figure 13.31. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, Till 2035 (USD Million)
• Figure 13.32. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, Till 2035 (USD Million)
• Figure 13.33. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, Till 2035 (USD Million)
• Figure 13.34. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, Till 2035 (USD Million)
• Figure 13.35. In Silico Drug Discovery Services Market for Large Molecules for Others, Till 2035 (USD Million)
• Figure 13.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor (USD Million)
• Figure 13.37. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, Till 2035 (USD Million)
• Figure 13.38. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, Till 2035 (USD Million)
• Figure 13.39. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions (USD Million)
• Figure 13.40. In Silico Drug Discovery Services Market for Large Molecules in North America (USD Million)
• Figure 13.41. In Silico Drug Discovery Services Market for Large Molecules in the US, Till 2035 (USD Million)
• Figure 13.42. In Silico Drug Discovery Services Market for Large Molecules in Canada, Till 2035 (USD Million)
• Figure 13.43. In Silico Drug Discovery Services Market for Large Molecules in Europe (USD Million)
• Figure 13.44. In Silico Drug Discovery Services Market for Large Molecules in Germany, Till 2035 (USD Million)
• Figure 13.45. In Silico Drug Discovery Services Market for Large Molecules in France, Till 2035 (USD Million)
• Figure 13.46. In Silico Drug Discovery Services Market for Large Molecules in the UK, Till 2035 (USD Million)
• Figure 13.47. In Silico Drug Discovery Services Market for Large Molecules in Italy, Till 2035 (USD Million)
• Figure 13.48. In Silico Drug Discovery Services Market for Large Molecules in Spain, Till 2035 (USD Million)
• Figure 13.49. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, Till 2035 (USD Million)
• Figure 13.50. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World (USD Million)
• Figure 13.51. In Silico Drug Discovery Services Market for Large Molecules in China, Till 2035 (USD Million)
• Figure 13.52. In Silico Drug Discovery Services Market for Large Molecules in India, Till 2035 (USD Million)
• Figure 13.53. In Silico Drug Discovery Services Market for Large Molecules in Japan, Till 2035 (USD Million)
• Figure 14.1. Upcoming Trends in Drug Discovery: Future Growth Opportunities